Innovative Technologies Development Foundation
4220 Shawnee Mission Parkway, Suite 350B
Fairway KS 66205
Web and Phone Contact
Telephone (816) 679-2915
Mission Statement
ITD Foundation (IDTF) is a collaborative nonprofit organization dedicated to accelerate development of early stage health care technologies. Currently, we have selected the development of:
  1. Rapid, point-of-injury, accurate methods for early diagnosis of subacute brain injuries (SBI) sustained from blows to the head
  2. Therapeutics that prevent the associated long term sequelae of SBI such as cognitive decline, Alzheimer’s Disease (AD) and chronic traumatic encephalopathy (CTE)
CEO/Executive Director
Board Chair TBD TBD
Board Chair Company Affiliation
History and Background
Year of Incorporation 2003
Financial Summary
Revenue Expense Area Graph

Comparing revenue to expenses shows how the organizations finances fluctuate over time.

Source: IRS Form 990

Net Gain/Loss:    in 
Note: When component data are not available, the graph displays the total Revenue and/or Expense values.
Mission Statement
ITD Foundation (IDTF) is a collaborative nonprofit organization dedicated to accelerate development of early stage health care technologies. Currently, we have selected the development of:
  1. Rapid, point-of-injury, accurate methods for early diagnosis of subacute brain injuries (SBI) sustained from blows to the head
  2. Therapeutics that prevent the associated long term sequelae of SBI such as cognitive decline, Alzheimer’s Disease (AD) and chronic traumatic encephalopathy (CTE)
Background Statement
  • At the outset, ITDF received tax-exempt status in partnership with SUNY Binghamton School of Business and secured initial funding from the NY State Economic Development Administration to develop an advanced course in entrepreneurship to write business plans for portfolio projects of the SUNY Tech Transfer Office.
  • That lead to launching three start-up corporations and performing operations and development functions; two received follow-on investments and are still in operation.
  • ITDF secured start-up funding, and managed a program to generate equity-based payback of loan debt to facilitate start-up investments.
  • ITDF then moved and partnered with the Univ. of Georgia and a spin-off corporation to form a statewide Tele-Stroke/Telemedicine entity to enhance medical treatment options in remote access communities.
  • ITDF moved again to Kansas and agreed to work with pHLOGISTIX to advance its strategic plan for diagnostics of mild TBI (mTBI) and therapeutics against mTBI and subsequent neurodegenerative disorders.
Impact Statement
  • We have successfully set into motion a formal agreement to manage fundraising efforts and collaborative research agreements between contract research and manufacturing organizations and an identified early stage company focused on the diagnosis and treatment of mild traumatic brain injury (TBI).
  • We have increased the size and composition of the Board to include Ph.D.-level scientists with preclinical drug discovery and contract research organization (CRO) experience.
  • We have outlined a plan with expert academic and CRO laboratories to quantify unique analyte biomarkers to be used in conjunction with experimental TBI studies.
  • We have entered into discussion with a nonprofit national biomedical engineering laboratory expert in medical devices and analytic tools to develop a microfluidic “on-a-chip” handheld device to enable fast, accurate measures of biomarkers at the point-of-injury.
Our primary goal is to secure philanthropic donations so that we can execute our business plan.
  • Within this primary goal, we seek to obtain proof of concept evidence that can be used to support grant proposals to the NIH, Department of Defense and other federal agencies for the development of the diagnostic platform and aligned therapeutic (a “theranostic”).
  • We also plan to add Board members with significant experience in corporate finance, venture capital and private equity investment, medical device and drug development.
  • From that pool of 9-11, we plan to select a Chair and Executive Director.
Needs Statement
  • Funding for novel technology development.
  • Funding for model confirmation studies.
  • Funding for preclinical animal efficacy studies.
  • Funding to support operations.
  • Funding to manufacture sufficient quantities of non-GLP grade of biotherapeutic agent(s).
Service Categories
Biomedicine & Bioengineering Research
Neurology & Neuroscience Research
Small Business Development
Areas of Service
CEO/Executive Director/Board Chair Statement
Those of us who have grown up playing contact sports in middle or high school, college, or for recreation as adults, recognize the frequency of blows to the head during play, especially in practice situations. It has become apparent that these previously-ignored, seemingly minor injuries accumulate, causing significant neurological problems later in life. Emerging technologies directly address this issue, will have a major impact on the diagnosis and treatment of concussions and will prevent development of neurodegenerative diseases.
There is a significant need for a quantitative in-the-field determination (point-of-care/point-of-injury) of the severity and prognosis of concussions sustained during sporting activities, accidents involving motor vehicles, domestic violence, military activities, falls in children and the elderly, accidents that occur on-the-job, and in companion animals who suffer blows to the head.
We have identified expert research neurologists with well-developed hypotheses and solid scientific rationale for a specific approach to this problem, along with service providers with expertise in bioanalytical method development and point-of-care diagnostic and therapeutic delivery devices.
We will manage the program, bring together these expert resources, and develop the proof of concept to the point where sustainable funding can be realized from commercial sources.
Category Medical Research, General/Other Head Injury Research
Population Served General/Unspecified, ,
Short-Term Success Quickly and efficiently hit Go/No Go decision points in the development plan, and move forward with adjustment if necessary.
Long-Term Success Our primary goal is to bridge the gap between promising concept and external sustainability. We will consider ourselves successful if our clients attain a degree of independence, and have in place all the necessary components to execute their business model.
Program Success Monitored By Demonstration and widespread acceptance in the above-and below-mentioned venues and environments.
Examples of Program Success
This is a new program for ITDF, consequently, we have no stories or statistics that directly address success in this new area. We envision a handheld device that is present during soccer, hockey and football games, at motor vehicle races and construction sites, during military training and at forward operating positions worldwide. These devices will enable non-medically trained personnel to quickly establish the presence of mTBI for back-to-play or return-to-work decisions. A small drop of blood will be scanned in this device, close to the time point of injury, for the presence of specific molecules that have leaked out of damaged cells in the central nervous system and across the blood brain barrier.
Results will also direct treatment options for the 3 million annual emergency room visits in the U.S. that include a diagnosis of traumatic brain injury, as well as the additional millions who have sustained seemingly minor “dings” to the head that may progress to permanent damage.
There is an even greater need for a therapeutic intervention that halts the progression of the resultant mTBI or repeated neurological damage to AD or CTE.  
To date pharmacological intervention is limited to decreasing the symptoms of mTBI, which may include:
• Pain
• Sensory or motor alterations
• Emotional, cognitive, or behavioral problems
• Psychotic or neurological issues
• Disturbances of sleep or endocrine function
Our aim is to develop a novel pharmacological agent that will be administered soon after injury, which will modify the neuroinflamatory response to mTBI, and decrease not only these symptoms, but also their underlying cause.
Category Medical Research, General/Other Head Injury Research
Population Served General/Unspecified, ,
Short-Term Success The drug development process involves a series of steps, each contingent on the success of the previous steps. As a non-profit foundation ITDF will encourage undertaking strategies for rapidly reaching success or failure points both with CROs and early stage biotechnology companies. That is, to adopt the attitude that if a compound is to fail in the process, then we shall ensure that it fails as soon as possible, with the least amount of resources spent. This will force early adjustments with minimal repeat testing.
Long-Term Success Success will be measured in clinical trials where it can be demonstrated that this compound reduces the appearance of specific biomarkers in plasma, and that this reduction reflects the neuroprotective quality of the compound.
Program Success Monitored By Peer-reviewed approval of submitted grant proposals, research communications, regulatory submissions, and development partnerships.
Examples of Program Success
As with the above program, we anticipate the following scenario. In a competitive league soccer game, two 12-year old boys collide heads and both briefly act oddly but do not lose consciousness. They are removed from the game, examined on the sideline, and a measurement is taken using the above Neurodiagnostic device. They both show slightly elevated biomarkers, but otherwise appear healthy and normal.
One set of parents elects to have their son examined in the ER; the other set of parents dismiss the event and take their son home. In the ER, another measurement reveals an elevation of biomarker(s), which prompts the attending physician to administer a dose of the anti-inflammatory Neurotherapeutic. Follow up exams, measurements, and repeated dosage is given three times over the next month until the biomarker has returned to baseline.
The untreated boy complains of headaches for a week, occasional dizziness, and at the end of the semester his teachers note some disruptive behavioral occurrences (probably manifesting post-concussion syndrome—PCS-- and possibly post-traumatic stress disorder--PTSD). Forty years later the untreated boy is diagnosed with chronic traumatic encephalopathy (CTE). The boy treated with anti-inflammatory Neurotherapeutic remains cognitively robust deep into his eighth or even ninth decade.
CEO Comments The Board is in the process of updating all information, including the mission statement and Advisory Board membership. It is in the process of modifying the Foundation's name to Ahead Tech to more closely match its current mission.
Executive Director/CEO
Term Start Sept 2015
Co-CEO/Executive Director
Term Start
Compensation Last Year
Senior Staff
Title Development
Paid Full-Time Staff 1
Paid Part-Time Staff 1
Volunteers 2
Plans & Policies
Organization Has a Fundraising Plan Yes
Organization Has a Strategic Plan Yes
Management Succession Plan Under Development
Organization Policy and Procedures Under Development
Nondiscrimination Policy Under Development
Document Destruction Policy No
Board Chair
Board Chair TBD TBD
Term Sept 2015 to Sept 2017
Board Members
Barry W. Festoff M.D.
Thomas F. Krol Pharm D, CLPKansas Bioscience Authority (KBA)
Board Demographics - Ethnicity
African American/Black 0
Asian American/Pacific Islander 0
Caucasian 2
Hispanic/Latino 0
Native American/American Indian 0
Other 0 0
Board Demographics - Gender
Male 2
Female 0
Unspecified 0
Board Term Lengths 3
Board Term Limits 3
Written Board Selection Criteria? Under Development
Written Conflict of Interest Policy? Yes
Number of Full Board Meetings Annually 1
Standing Committees
Advisory Board / Advisory Council
Fiscal Year Start Jan 01, 2015
Fiscal Year End Dec 31, 2015
Projected Revenue $25,000
Projected Expenses $150,000
IRS Letter of Exemption
Foundation Comments
  • FY 2013, 2012, 2011: Financial data reported using internal financial documents provided by the agency.
Detailed Financials
Expense Allocation
Fiscal Year201320122011
Program Expense$0$0$0
Administration Expense$0$0$0
Fundraising Expense$0$0$0
Payments to Affiliates$0$0$0
Total Revenue/Total Expenses------
Program Expense/Total Expenses------
Fundraising Expense/Contributed Revenue0%----
Assets and Liabilities
Fiscal Year201320122011
Total Assets$15,400$0$0
Current Assets$15,400$0$0
Long-Term Liabilities$0$0$0
Current Liabilities$0$0$0
Total Net Assets$15,400$0$0
Short-Term Solvency
Fiscal Year201320122011
Current Ratio: Current Assets/Current Liabilities------
Long-Term Solvency
Fiscal Year201320122011
Long-Term Liabilities/Total Assets0%----
Top Funding Sources
Fiscal Year201320122011
Top Funding Source & Dollar Amount -- -- --
Second Highest Funding Source & Dollar Amount -- -- --
Third Highest Funding Source & Dollar Amount -- -- --
Capital Campaign
Currently in a Capital Campaign? No
Organization Name Innovative Technologies Development Foundation
Address 4220 Shawnee Mission Parkway, Suite 350B
Fairway, KS 66205
Primary Phone (816) 679-2915
Contact Email
Board Chair TBD TBD
Year of Incorporation 2003